Methods for treating hepatocellular carcinoma
The present invention provides methods and compositions for treating hepatocellular carcinoma (HCC) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating HCC comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent, such as an agent that inhibits microtubule disassembly.
1. A method of treating hepatocellular carcinoma (HCC) in an individual in need thereof, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, and b) an effective amount of at least one other agent, wherein said other agent is a small interference RNA (siRNA) against STMN1 or an antisense oligonucleotide against STMN1.
2. The method of claim 1 , wherein the nanoparticle composition and the other agent are administered simultaneously or sequentially.
3. The method of claim 1 , wherein the nanoparticle composition and the other agent are administered concurrently.
4. The method of claim 1 , wherein the other agent inhibits a molecule that promotes microtubule disassembly directly or indirectly.
5. The method of claim 1 , wherein the other agent is an siRNA against STMN1.
6. The method of claim 1 , wherein the HCC is liver cell carcinoma, fibrolamellar variant of HCC, or mixed hepatocellular cholangiocarcinoma.
7. The method of claim 1 , wherein the HCC is early stage HCC, non-metastatic HCC, primary HCC, advanced HCC, locally advanced HCC, metastatic HCC, HCC in remission, recurrent HCC, HCC in an adjuvant setting, or HCC in a neoadjuvant setting.
8. The method of claim 1 , wherein the composition comprising nanoparticles comprising a taxane and albumin is administered parenterally.
9. The method of claim 8 , wherein the composition comprising nanoparticles comprising a taxane and albumin is administered intravenously, intraarterially, intrahepatically, or intraportally.
10. The method of claim 1 , wherein the taxane is paclitaxel.
11. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
12. The method of claim 11 , wherein the nanoparticles in the composition have an average diameter of less than about 200 nm.
13. The method of claim 1 , wherein the taxane in the nanoparticles are coated with albumin.
14. The method of claim 1 , wherein the individual is human.